Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC in castrate-resistant prostate cancer with bone metastasis
NCT02864784Phase 1Withdrawn
- Sponsor
- Amorphical
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Hydrogel Systems, Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in prostate cancer (PCa) comparing Amorphous calcium carbonate with Placebo (2 arms). Primary endpoint: Changes in the number of Skeletal Related Events at 12 weeks. Planned start Jun 2022; status: withdrawn.
02
Drugs
amorphous calcium carbonate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02864784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864784.